|Bid||26.00 x 600|
|Ask||30.85 x 700|
|Day's range||27.13 - 27.74|
|52-week range||23.29 - 29.93|
|PE ratio (TTM)||45.43|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.
Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.
Boston Scientific (BSX) claims its Spectra WaveWriter Spinal Cord Stimulator System to combine both paresthesia-based and sub-perception therapies to target a specific area of pain.
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.
Shares of Boston Scientific Corp. rose 1.7% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its Spectra WaveWriter spinal cord simulator system, a ...
Boston Scientific (BSX) pulls out all the stops to strengthen its core business as well as invest more in the global markets. This also gets reflected in its preliminary sales results.
Boston Scientific (BSX) climbed to the top of the S&P 500 on Tuesday on its upbeat fourth-quarter forecast. Boston Scientific climbed $2.15, or 8.3%, to $27.96, while the S&P 500 gained 3.58 points, or ...
Shares of Boston Scientific Corp. surged 5.2% in morning trade Tuesday, enough to make them the second-biggest gainer among S&P 500 components, after the medical technology company provided an upbeat sales ...
Boston Scientific (BSX) has been in litigation for five years over product liability claims involving its pelvic mesh implant.
On December 11, 2017, Boston Scientific (BSX) stock rose 3%, triggered by FDA approval of its Vercise DBS (deep brain stimulation) system.
On December 8, 2017, Needham & Company analyst Mike Matson upgraded Boston Scientific (BSX) stock from a "buy" to a "strong buy."
On December 8, 2017, Needham & Company upgraded its rating on BSX stock from a "buy" to a "strong buy" and maintained its price target of $32.
Boston Scientific (BSX) stock closed at $25.80 on December 18, 2017. It was trading lower than its 50-day moving average of $27.10 as well as its 200-day moving average of $27.80.